Versant Venture Capital IV, L.P. is 10% Owner at CRISPR Therapeutics AG (CRSP). They have made 1 open-market trade across 1 company since 2018, most recently 2026-10-14.
CIK 0001674416
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| NARI | 5,745,542 | $459.5M |
| CRSP | 15,486 | $763K |
| Total | $460.2M |
Shares reported on the most recent Form 4, priced at the 2026-10-16 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.